Innovus Pharmaceuticals Inc (OTCMKTS:INNV) How Will The Market Respond to Trial News?, a leading financial news portal, released an article examining the benefits of RecalMax™, a new product from Innovus Pharmaceuticals Inc (OTCMKTS:INNV).

REDONDO BEACH, CA–(Marketwired – Sep 13, 2016) –, a leading financial news and information portal offering free real time public company filing alerts, announces an article examining the potential of the newly-launched brain health supplement RecalMax™.

Innovus Pharma’s ( OTCQB : INNV ) RecalMax™ was tested in a four-month human clinical trial on 72 patients with low memory and learning. After taking one capsule twice a day for 16 weeks, patients reported a 115% increase in the recall of words and names, a 49.5% increase in maintaining thoughts when distracted, and a 35% increase in processing speed. The supplement was also well-tolerated with no serious adverse events reported.

Parkinson’s disease and Alzheimer’s disease are the two most prevalent medical conditions falling into the neurodegenerative market, estimated in the neighborhood of $11 billion annually. Both are characterized by neurological problems affecting memory, learning, and nerve function — eventually leading to premature death.

Innovus Pharma estimates that the immediate market for a product like RecalMax™ could be worth around $3 billion, since it helps treat some of the major endpoints associated with neurodegenerative diseases. Management believes that it can capture enough of the market to generate about $5 million in annual revenue by deploying the treatment across its well-established Beyond Human Platform and online marketing channels throughout the U.S. and other regions of the world.

To read the full article, please click here:


Founded in 2004, provides free real time filing alerts to over 600,000 registered members and offers services to help public companies grow their audience of interested investors.



The average daily trading volume (ADTV) is the number of commodities traded per day on average over a specific time period.  Trading activity is tied to the liquidity of a stock.  If there is high average daily trading volume, the security can be moved easily and has high liquidity.  In contrast, if trading volume is low, the commodity will usually be less expensive due to the fact that people are not as eager to buy.   Innovus Pharmaceuticals Inc (OTCMKTS:INNV)’s average trading volume is 4387000.

Are Innovus Pharmaceuticals Inc (OTCMKTS:INNV) Shares Ready to Explode?  Sign up to our Newsletter to be the First to Know

Sign up to get our Free Penny Stock Picks Before the Street!

Innovus Pharmaceuticals Inc (OTCMKTS:INNV) shares closed the most recent session at $0.33 moving from the previous open of $0.03.  This is compared to the stock’s 52-week high of 0.66 and 52-week low of 0.03.

It’s important to use market capitalization (market cap) to show the size of a company because company size is a basic characteristic in which investors are interested.  Luckily, it’s easy to calculate: Market Capitalization = Number of Shares Outstanding x Price.  For example, if a company has 10 million shares selling at $100/share, it would have a market cap of $1 billion.  Currently, Innovus Pharmaceuticals Inc (OTCMKTS:INNV)’s market cap is $33990000.

Sign Up to Receive Breaking Alerts on Stocks That Are Primed to Make a Run in the Bar Below.

Sign up to get our Free Penny Stock Picks Before the Street!

Disclaimer: The views, opinions, and information expressed in this article are those of the authors and do not necessarily reflect the official policy or position of any company stakeholders, financial professionals, or analysts. Examples of analysis performed within this article are only examples. They should not be utilized to make stock portfolio or financial decisions as they are based only on limited and open source information. Assumptions made within the analysis are not reflective of the position of any analysts or financial professionals.



BRKK is One of the Most Under the Radar Penny Stocks We've Ever Seen. View the free report here.


Related posts

Leave a Comment